Home » Stocks » SKYE

Skye Bioscience, Inc. (SKYE)

Stock Price: $0.0890 USD -0.0010 (-1.11%)
Updated May 10, 2021 3:59 PM EDT - Market closed
Market Cap 31.50M
Revenue (ttm) n/a
Net Income (ttm) -6.38M
Shares Out 336.88M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $0.0890
Previous Close $0.0900
Change ($) -0.0010
Change (%) -1.11%
Day's Open 0.1000
Day's Range 0.0870 - 0.1000
Day's Volume 1,920,004
52-Week Range 0.0680 - 0.2460

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

San Diego, Calif, April 22, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived mole...

2 weeks ago - GlobeNewsWire

San Diego, Calif, April 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived mole...

3 weeks ago - GlobeNewsWire

Skye Bioscience Inc. was a sponsor at the Benzinga Cannabis Capital Conference on February 25-26, 2021. The information contained in this article in no way represents investment advice or opinion on the...

1 month ago - Benzinga

San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-...

2 months ago - GlobeNewsWire

San Diego, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-...

2 months ago - GlobeNewsWire

The following article is sponsored by Skye Bioscience, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is inte...

2 months ago - Benzinga

San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-d...

Other stocks mentioned: EMBI
3 months ago - GlobeNewsWire

Skye Bioscience, formally Emerald Bioscience, was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in no ...

3 months ago - Benzinga

Name change reflects Company's evolution, renewed team and strategic focus on advancing its lead compound into human trials Company to trade under ticker SKYE effective January 19, 2021 Name change refl...

Other stocks mentioned: EMBI
3 months ago - GlobeNewsWire

San Diego, Calif, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid...

Other stocks mentioned: EMBI
3 months ago - GlobeNewsWire

San Diego, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a biopharmaceutical company focused on developing differentiated, proprietary can...

Other stocks mentioned: EMBI
4 months ago - GlobeNewsWire

Drug Delivery and Translational Research article highlights significantly better drug load and duration of activity of prodrug of THC compared to leading commercial drugs for treating glaucoma

Other stocks mentioned: EMBI
4 months ago - GlobeNewsWire

The rapid innovation and growth in biotechnology is being used to define, validate, and enhance therapeutic outcomes from cannabinoids. The results could prove highly valuable to patients, as well as th...

Other stocks mentioned: EMBI
5 months ago - Benzinga

Renewed team and capital focused on advancing lead compound for glaucoma into human studies

Other stocks mentioned: EMBI
7 months ago - GlobeNewsWire

San Diego, CA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI a preclinical-stage biopharmaceutical company focused on the development of proprietary first-in-class molecules...

Other stocks mentioned: EMBI
8 months ago - GlobeNewsWire

Renewed team and capital focused on advancing lead compound for glaucoma into clinical development Renewed team and capital focused on advancing lead compound for glaucoma into clinical development

Other stocks mentioned: EMBI
8 months ago - GlobeNewsWire

Renewed team and capital focused on advancing lead compound for glaucoma into clinical development

Other stocks mentioned: EMBI
9 months ago - GlobeNewsWire

Long Beach, CA, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address glo...

Other stocks mentioned: EMBI
9 months ago - GlobeNewsWire

Long Beach, CA, July 31, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address gl...

Other stocks mentioned: EMBI
9 months ago - GlobeNewsWire

Bio-engineered analog of CBD (CBDVHS) exhibited highly significant potency when compared to CBD in lowering biomarkers associated with inflammation and fibrosis in a validated human tissue model of ocul...

Other stocks mentioned: EMBI
11 months ago - GlobeNewsWire

GW Pharmaceuticals benefiting from competitors' setbacks.

Other stocks mentioned: EMBI, GWPH
2 years ago - Seeking Alpha

After reporting some strong results from its studies last month, cannabinoid biopharmaceutical company Emerald Bioscience Inc recently made headlines again.

Other stocks mentioned: EMBI
2 years ago - Benzinga

About SKYE

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based therapeutics for the treatment of infectious diseases. The company's lead product candidate is THCVHS, which is in preclinical trials for the treatment of glaucoma. It is also developing CBDVHS that is in preclinical trials to treat various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy; and Cannabinoid Cocktail for the treatment of anti-infective diseases. The company was formerly known... [Read more...]

Industry
Biotechnology
Founded
2012
CEO
Brian Murphy
Employees
6
Stock Exchange
OTCMKTS
Ticker Symbol
SKYE
Full Company Profile

Financial Performance

Financial Statements